Home › Funds › ADAGE CAPITAL PARTNERS GP, L.L.C. › ROIV

ADAGE CAPITAL PARTNERS GP, L.L.C. position in ROIV

ROIVANT SCIENCES LTD · Health Care

ADAGE CAPITAL PARTNERS GP, L.L.C. reported holding 10,349,328 shares of ROIV (ROIVANT SCIENCES LTD) in its Q2 2026 13F filing — a position valued at US$366.3M, representing 0.51% of its reported portfolio and ranking #29 among its reported holdings. ADAGE CAPITAL PARTNERS GP, L.L.C. has disclosed ROIV holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)10.35M sh
Reported value held$366.26M
Portfolio Weight0.51%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How ADAGE CAPITAL PARTNERS GP, L.L.C.'s ROIV position evolved

ADAGE CAPITAL PARTNERS GP, L.L.C. first disclosed a stake in ROIV in Q3 2023 at 6,200,000 shares (US$72.4M). The position peaked in Q2 2026 at 10,349,328 shares, worth US$366.3M. Across 12 filings, ADAGE CAPITAL PARTNERS GP, L.L.C. increased the stake 4 time(s), trimmed it 6 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 10,349,328 shares valued at US$366.3M — a reduction of -2,444,769 shares quarter over quarter.. Notable position changes include a 46% increase in Q3 2024 (shares rose 3% over the following quarter), a 247% increase in Q3 2025 (shares rose 43% over the following quarter), a 48% increase in Q4 2025 (shares rose 28% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 6.20M $72.42M New
Q4 2023 5.28M $59.24M Reduce
Q1 2024 3.93M $41.47M Reduce
Q2 2024 3.93M $41.59M Hold
Q3 2024 5.75M $66.41M Add
Q4 2024 5.72M $67.67M Reduce
Q1 2025 3.82M $38.54M Reduce
Q2 2025 2.08M $23.47M Reduce
Q3 2025 7.23M $109.43M Add
Q4 2025 10.68M $231.71M Add
Q1 2026 12.79M $354.40M Add
Q2 2026 10.35M $366.26M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ROIV and 13F data

ROIV (ROIVANT SCIENCES LTD) is a Health Care company. 63 other funds we track also report a position in ROIV — the largest reported positions include QVT Financial LP (US$839.6M), Farallon Capital Management (US$506.4M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$506.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ROIV

All ROIV fund holders →

FAQ

How long has ADAGE CAPITAL PARTNERS GP, L.L.C. held ROIV?

ADAGE CAPITAL PARTNERS GP, L.L.C. has disclosed ROIV holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is ADAGE CAPITAL PARTNERS GP, L.L.C.'s current position in ROIV?

As of Q2 2026, ADAGE CAPITAL PARTNERS GP, L.L.C. holds 10.35M shares of ROIV (ROIVANT SCIENCES LTD), valued at $366.26M, representing 0.51% of its reported portfolio and ranking #29.

Has ADAGE CAPITAL PARTNERS GP, L.L.C. been buying or selling ROIV?

In the latest 13F filing (Q2 2026), ADAGE CAPITAL PARTNERS GP, L.L.C. reduced its position in ROIV. The position peaked in Q2 2026 at 10.35M shares.

Which other funds hold ROIV?

Other major institutional holders of ROIV include QVT Financial LP, Farallon Capital Management, FARALLON CAPITAL MANAGEMENT, L.L.C., among 63 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.